Lipocine (NASDAQ:LPCN) Given Buy Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Lipocine (NASDAQ:LPCN) in a research note released on Wednesday,Benzinga reports. HC Wainwright currently has a $8.00 price objective on the specialty pharmaceutical company’s stock. HC Wainwright also issued estimates for Lipocine’s Q3 2025 earnings at ($0.56) EPS, Q4 2025 earnings at ($0.55) EPS, FY2025 earnings at ($1.87) EPS, Q1 2026 earnings at ($0.55) EPS, Q2 2026 earnings at ($0.55) EPS, Q3 2026 earnings at ($0.50) EPS, Q4 2026 earnings at ($0.46) EPS and FY2026 earnings at ($2.06) EPS.

Several other equities analysts also recently commented on LPCN. Wall Street Zen initiated coverage on shares of Lipocine in a research note on Saturday, May 17th. They issued a “hold” rating for the company. Alliance Global Partners raised shares of Lipocine to a “strong-buy” rating in a research note on Monday, August 11th. One analyst has rated the stock with a Strong Buy rating and one has given a Buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Strong Buy” and an average price target of $9.00.

Lipocine Trading Up 3.3%

NASDAQ LPCN opened at $3.11 on Wednesday. The firm has a market capitalization of $16.86 million, a price-to-earnings ratio of -3.57 and a beta of 1.24. The firm’s 50 day simple moving average is $3.15 and its 200 day simple moving average is $3.26. Lipocine has a 1 year low of $2.68 and a 1 year high of $6.17.

Lipocine (NASDAQ:LPCN) last posted its quarterly earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.41). The firm had revenue of $0.62 million for the quarter, compared to analyst estimates of $1.00 million.

Hedge Funds Weigh In On Lipocine

An institutional investor recently raised its position in Lipocine stock. Geode Capital Management LLC grew its holdings in shares of Lipocine Inc. (NASDAQ:LPCN) by 6.0% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 57,464 shares of the specialty pharmaceutical company’s stock after acquiring an additional 3,248 shares during the period. Geode Capital Management LLC owned about 1.07% of Lipocine worth $280,000 as of its most recent SEC filing. Institutional investors own 9.11% of the company’s stock.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.